The pathways related to glutamine metabolism, glutamine inhibitors and their implication for improving the efficiency of chemotherapy in triple-negative breast cancer
- PMID: 34083056
- DOI: 10.1016/j.mrrev.2021.108366
The pathways related to glutamine metabolism, glutamine inhibitors and their implication for improving the efficiency of chemotherapy in triple-negative breast cancer
Abstract
Breast cancer (BC) is a heterogeneous cancer with multiple subtypes affecting women worldwide. Triple-negative breast cancer (TNBC) is a prominent subtype of BC with poor prognosis and an aggressive phenotype. Recent understanding of metabolic reprogramming supports its role in the growth of cancer cells and their adaptation to their microenvironment. The Warburg effect is characterized by the shift from oxidative to reductive metabolism and external secretion of lactate. The Warburg effect prevents the use of the required pyruvate in the tricarboxylic acid (TCA) cycle progressing through pyruvate dehydrogenase inactivation. Therefore, it is a major regulatory mechanism to promote glycolysis and disrupt the TCA cycle. Glutamine (Gln) can supply the complementary energy for cancer cells. Additionally, it is the main substrate to support bioenergetics and biosynthetic activities in cancer cells and plays a vital role in a wide array of other processes such as ferroptosis. Thus, the switching of glucose to Gln in the TCA cycle toward reductive Gln metabolism is carried out by hypoxia-inducible factors (HIFs) conducted through the Warburg effect. The literature suggests that the addiction of TNBC to Gln could facilitate the proliferation and invasiveness of these cancers. Thus, Gln metabolism inhibitors, such as CB-839, could be applied to manage the carcinogenic properties of TNBC. Such inhibitors, along with conventional chemotherapy agents, can potentially improve the efficiency and efficacy of TNBC treatment. In this review, we discuss the associations between glucose and Gln metabolism and control of cancer cell growth from the perspective that Gln metabolism inhibitors could improve the current chemotherapy drug effects.
Keywords: Apoptosis; Ferroptosis; Glutaminase inhibitors; Glutamine metabolism; TCA cycle; Triple-negative breast cancer; Warburg effect.
Copyright © 2021 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors report no declarations of interest.
Similar articles
-
Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.BMC Cancer. 2020 May 25;20(1):470. doi: 10.1186/s12885-020-06885-3. BMC Cancer. 2020. PMID: 32450839 Free PMC article.
-
Glutamine metabolism in breast cancer and possible therapeutic targets.Biochem Pharmacol. 2023 Apr;210:115464. doi: 10.1016/j.bcp.2023.115464. Epub 2023 Feb 26. Biochem Pharmacol. 2023. PMID: 36849062 Review.
-
Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition.PLoS One. 2017 Sep 26;12(9):e0185092. doi: 10.1371/journal.pone.0185092. eCollection 2017. PLoS One. 2017. PMID: 28950000 Free PMC article.
-
[18F](2S,4R)4-Fluoroglutamine PET Detects Glutamine Pool Size Changes in Triple-Negative Breast Cancer in Response to Glutaminase Inhibition.Cancer Res. 2017 Mar 15;77(6):1476-1484. doi: 10.1158/0008-5472.CAN-16-1945. Epub 2017 Feb 15. Cancer Res. 2017. PMID: 28202527 Free PMC article.
-
Metabolic reprogramming in triple-negative breast cancer.Cancer Biol Med. 2020 Feb 15;17(1):44-59. doi: 10.20892/j.issn.2095-3941.2019.0210. Cancer Biol Med. 2020. PMID: 32296576 Free PMC article. Review.
Cited by
-
The expression of miR-513c and miR-3163 was downregulated in tumor tissues compared with normal adjacent tissue of patients with breast cancer.BMC Med Genomics. 2021 Jul 7;14(1):180. doi: 10.1186/s12920-021-01029-3. BMC Med Genomics. 2021. PMID: 34233668 Free PMC article.
-
α-Ketoglutaramate-A key metabolite contributing to glutamine addiction in cancer cells.Front Med (Lausanne). 2022 Nov 4;13:1035335. doi: 10.3389/fmed.2022.1035335. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36404951 Free PMC article. No abstract available.
-
Mesothelioma cancer cells are glutamine addicted and glutamine restriction reduces YAP1 signaling to attenuate tumor formation.Mol Carcinog. 2023 Apr;62(4):438-449. doi: 10.1002/mc.23497. Epub 2022 Dec 23. Mol Carcinog. 2023. PMID: 36562471 Free PMC article.
-
KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression.Front Cell Dev Biol. 2023 Apr 20;11:1147676. doi: 10.3389/fcell.2023.1147676. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37152291 Free PMC article. Review.
-
The Role of Glutamine and Glutaminase in Pulmonary Hypertension.Front Cardiovasc Med. 2022 Mar 2;9:838657. doi: 10.3389/fcvm.2022.838657. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35310969 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources